Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):781–785. doi: 10.1038/bjc.1990.379

Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study.

M Danova 1, A Riccardi 1, G Ucci 1, R Luoni 1, M Giordano 1, G Mazzini 1
PMCID: PMC1971520  PMID: 2245170

Abstract

Using bivariate flow cytofluorometry, we have determined the nuclear DNA distribution and the expression of the p21 protein (coded by the Ha-ras oncogene) in the bone marrow (BM) cells of five solid tumour patients having histologically normal BM and in those of 57 patients with plasma cell dyscrasia (28 with monoclonal gammopathies of undertermined significance, MGUS, and 29 with multiple myeloma, MM). All normal and MGUS and 21/29 (72.4%) MM BM had diploid modal DNA content and 8/29 (27.6%) MM BM had both diploid and hyperdiploid cell populations. In normal and MGUS BM, the level of the p21 oncoprotein was low and uniform in all G0/G1, S and G2 cells (median fluorescence values in arbitrary units were 6.1 and 7.5, respectively). The level of p21 was increased both in different aliquots of G0/G1 cells and in the S and G2 cells in diploid MM (median value for G0/G1 cells was 20), and especially in MM with hyperdiploid clones (median value for hyperdiploid cells was 40.5, P less than 0.005 with respect to normal and MGUS BM and less than 0.005 with respect to diploid MM BM). The p21 expression was greater in patients with advanced (stage III) than in earlier MM (stages I + II) (P less than 0.005), and it was directly related to the BMPC infiltration (r = 0.7; P less than 0.005). Since p21 expression is greater in MM than in both normal and MGUS BM, Ha-ras could be involved in the malignant plasma cell transformation that distinguishes MM from MGUS.

Full text

PDF
781

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreeff M., Slater D. E., Bressler J., Furth M. E. Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines. Blood. 1986 Mar;67(3):676–681. [PubMed] [Google Scholar]
  2. Bar-Sagi D. ras proteins: biological effects and biochemical targets (review). Anticancer Res. 1989 Sep-Oct;9(5):1427–1437. [PubMed] [Google Scholar]
  3. Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989 Mar;73(4):865–879. [PubMed] [Google Scholar]
  4. Bishop J. M. Cellular oncogenes and retroviruses. Annu Rev Biochem. 1983;52:301–354. doi: 10.1146/annurev.bi.52.070183.001505. [DOI] [PubMed] [Google Scholar]
  5. Bos J. L., Verlaan-de Vries M., van der Eb A. J., Janssen J. W., Delwel R., Löwenberg B., Colly L. P. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987 Apr;69(4):1237–1241. [PubMed] [Google Scholar]
  6. Brouty-Boyé D., Wybier-Franqui J., Calvo C., Feunteun J., Gresser I. Reversibility of the transformed and neoplastic phenotype. IV. Effects of long-term interferon treatment of C3H/10T1/2 cells transformed by methylcholanthrene and SV40 virus. Int J Cancer. 1984 Jul 15;34(1):107–112. doi: 10.1002/ijc.2910340119. [DOI] [PubMed] [Google Scholar]
  7. Cooper G. M. Cellular transforming genes. Science. 1982 Aug 27;217(4562):801–806. doi: 10.1126/science.6285471. [DOI] [PubMed] [Google Scholar]
  8. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Giordano M., Danova M., Riccardi A., Mazzini G. Simultaneous detection of cellular ras p21 oncogene product and DNA content by two-parameter flow cytometry. Anticancer Res. 1989 May-Jun;9(3):799–803. [PubMed] [Google Scholar]
  10. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988 Feb;71(2):453–456. [PubMed] [Google Scholar]
  11. Greipp P. R. Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis. Blood Rev. 1989 Dec;3(4):222–236. doi: 10.1016/0268-960x(89)90030-1. [DOI] [PubMed] [Google Scholar]
  12. Hirai H., Okada M., Mizoguchi H., Mano H., Kobayashi Y., Nishida J., Takaku F. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood. 1988 Jan;71(1):256–258. [PubMed] [Google Scholar]
  13. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975 Jul;66(1):188–193. doi: 10.1083/jcb.66.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lin S. L., Garber E. A., Wang E., Caliguiri L. A., Schellekens H., Goldberg A. R., Tamm I. Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol. 1983 Sep;3(9):1656–1664. doi: 10.1128/mcb.3.9.1656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Liu E., Hjelle B., Morgan R., Hecht F., Bishop J. M. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature. 1987 Nov 12;330(6144):186–188. doi: 10.1038/330186a0. [DOI] [PubMed] [Google Scholar]
  16. Lundy J., Grimson R., Mishriki Y., Chao S., Oravez S., Fromowitz F., Viola M. V. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients. J Clin Oncol. 1986 Sep;4(9):1321–1325. doi: 10.1200/JCO.1986.4.9.1321. [DOI] [PubMed] [Google Scholar]
  17. McGrath J. P., Capon D. J., Goeddel D. V., Levinson A. D. Comparative biochemical properties of normal and activated human ras p21 protein. Nature. 1984 Aug 23;310(5979):644–649. doi: 10.1038/310644a0. [DOI] [PubMed] [Google Scholar]
  18. Neri A., Murphy J. P., Cro L., Ferrero D., Tarella C., Baldini L., Dalla-Favera R. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989 Nov 1;170(5):1715–1725. doi: 10.1084/jem.170.5.1715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pedersen-Bjergaard J., Janssen W. G., Lyons J., Philip P., Bartram C. R. Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res. 1988 Apr 1;48(7):1812–1817. [PubMed] [Google Scholar]
  20. Samid D., Chang E. H., Friedman R. M. Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun. 1984 Feb 29;119(1):21–28. doi: 10.1016/0006-291x(84)91612-7. [DOI] [PubMed] [Google Scholar]
  21. Shih T. Y., Weeks M. O. Oncogenes and cancer: the p21 ras genes. Cancer Invest. 1984;2(2):109–123. doi: 10.3109/07357908409020294. [DOI] [PubMed] [Google Scholar]
  22. Stewart C. C. Flow cytometric analysis of oncogene expression in human neoplasias. Arch Pathol Lab Med. 1989 Jun;113(6):634–640. [PubMed] [Google Scholar]
  23. Sweet R. W., Yokoyama S., Kamata T., Feramisco J. R., Rosenberg M., Gross M. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature. 1984 Sep 20;311(5983):273–275. doi: 10.1038/311273a0. [DOI] [PubMed] [Google Scholar]
  24. Thein S. L., Oscier D. G., Flint J., Wainscoat J. S. Ha-ras hypervariable alleles in myelodysplasia. Nature. 1986 May 1;321(6065):84–85. doi: 10.1038/321084a0. [DOI] [PubMed] [Google Scholar]
  25. Thor A., Horan Hand P., Wunderlich D., Caruso A., Muraro R., Schlom J. Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases. Nature. 1984 Oct 11;311(5986):562–565. doi: 10.1038/311562a0. [DOI] [PubMed] [Google Scholar]
  26. Tsuchiya H., Epstein J., Selvanayagam P., Dedman J. R., Gallick G., Alexanian R., Barlogie B. Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood. 1988 Aug;72(2):796–800. [PubMed] [Google Scholar]
  27. Ucci G., Riccardi A., Luoni R., Spriano P., Merlini G., Danova M., Cassano E., Molinari E., Ascari E. Serum thymidine kinase and beta-2 microglobulin in monoclonal gammopathies. Tumori. 1987 Oct 31;73(5):445–449. doi: 10.1177/030089168707300503. [DOI] [PubMed] [Google Scholar]
  28. Varmus H. E. The molecular genetics of cellular oncogenes. Annu Rev Genet. 1984;18:553–612. doi: 10.1146/annurev.ge.18.120184.003005. [DOI] [PubMed] [Google Scholar]
  29. Viola M. V., Fromowitz F., Oravez S., Deb S., Schlom J. ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med. 1985 May 1;161(5):1213–1218. doi: 10.1084/jem.161.5.1213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Watson J. V. Oncogenes, cancer and analytical cytology. Cytometry. 1986 Sep;7(5):400–410. doi: 10.1002/cyto.990070503. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES